Inogen, Inc.

How big is Inogen, Inc.?

As of Jun 18, Inogen, Inc. has a market capitalization of 174.23 million and reported net sales of 339.96 million with a net profit of -27.48 million over the latest four quarters. Shareholder's funds are at 173.86 million, and total assets amount to 296.19 million.

As of Jun 18, Inogen, Inc. has a market capitalization of 174.23 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of Net Sales for the latest four quarters is 339.96 million, while the sum of Net Profit for the same period is -27.48 million.<BR><BR>As of Dec 24, the reporting period shows Shareholder's Funds at 173.86 million and Total Assets at 296.19 million.

What does Inogen, Inc. do?

Inogen, Inc. is a medical technology company that develops and markets portable oxygen concentrators for patients with chronic respiratory conditions. As of March 2025, it reported net sales of $82 million and a net loss of $6 million, with a market cap of $174.23 million.

Overview: <BR>Inogen, Inc. is a medical technology company that develops, manufactures, and markets portable oxygen concentrators for patients with chronic respiratory conditions, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 82 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -6 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 174.23 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.60 <BR>Return on Equity: -12.38% <BR>Price to Book: 0.88<BR><BR>Contact Details: <BR>Address: 326 Bollay Dr, GOLETA CA: 93117-5550 <BR>Tel: ['1 805 5620500', '1 805 8798205'] <BR>Fax: 1 302 6365454 <BR>Website: https://www.inogen.com/

Should I buy, sell or hold Inogen, Inc.?

Who are in the management team of Inogen, Inc.?

As of March 2022, Inogen, Inc.'s management team includes Dr. Heath Lukatch (Independent Chairman), Mr. Scott Wilkinson (President and CEO), and several independent directors: Mr. Benjamin Anderson-Ray, Mr. Scott Beardsley, Mr. R. Scott Greer, Mr. Raymond Huggenberger, and Mr. Loren McFarland. This diverse team guides the company's governance and strategic direction.

As of March 2022, the management team of Inogen, Inc. includes the following individuals:<BR><BR>- Dr. Heath Lukatch, who serves as the Independent Chairman of the Board.<BR>- Mr. Scott Wilkinson, who is the President, Chief Executive Officer, and a Director.<BR>- Mr. Benjamin Anderson-Ray, an Independent Director.<BR>- Mr. Scott Beardsley, an Independent Director.<BR>- Mr. R. Scott Greer, an Independent Director.<BR>- Mr. Raymond Huggenberger, an Independent Director.<BR>- Mr. Loren McFarland, an Independent Director.<BR><BR>This team comprises a mix of executive leadership and independent directors, contributing to the governance and strategic direction of the company.

Is Inogen, Inc. overvalued or undervalued?

As of February 24, 2022, Inogen, Inc. is considered overvalued with a risky valuation grade due to negative financial metrics, including a P/E ratio and poor returns, significantly underperforming its peers and the S&P 500.

As of 24 February 2022, Inogen, Inc. has moved from an attractive to a risky valuation grade, indicating a significant deterioration in its financial outlook. The company is currently considered overvalued, as evidenced by its negative P/E ratio and poor return metrics. Key valuation ratios include a Price to Book Value of 0.90, an EV to EBITDA of -5.76, and an EV to Sales of 0.17, all of which suggest that the company is struggling to generate positive returns.<BR><BR>Inogen's peers, such as Bioventus, Inc. with a P/E of 72.81 and Semler Scientific, Inc. with a P/E of 32.26, highlight the disparity in valuation within the industry, as both are significantly outperforming Inogen. The company's recent stock performance has been disappointing, with a year-to-date return of -4.14% compared to the S&P 500's 12.22%, and a staggering 5-year return of -69.45% against the S&P 500's 96.61%, reinforcing the notion that Inogen is currently overvalued.

Is Inogen, Inc. technically bullish or bearish?

As of September 8, 2025, Inogen, Inc. shows a mildly bullish technical trend supported by positive MACD and Bollinger Bands, despite some bearish signals in daily moving averages and negative longer-term returns relative to the S&P 500.

As of 8 September 2025, the technical trend for Inogen, Inc. has changed from sideways to mildly bullish. The weekly MACD is bullish, and the monthly MACD is mildly bullish, supporting the positive outlook. Bollinger Bands are also bullish on both weekly and monthly time frames. However, daily moving averages indicate a mildly bearish stance, which tempers the overall bullish sentiment. The KST is bullish weekly but mildly bearish monthly, while Dow Theory shows a mildly bullish trend in both time frames. The On-Balance Volume is mildly bullish as well.<BR><BR>Inogen's recent performance shows a 1-week return of 2.69%, outperforming the S&P 500's 1.05%, and a strong 1-month return of 16.42% compared to the S&P 500's 2.33%. However, year-to-date and longer-term returns remain negative relative to the S&P 500. Overall, the current technical stance is mildly bullish, driven primarily by the positive MACD and Bollinger Bands.